NCT02018003

Brief Summary

The purpose of this study is to assess the women's quality of life, who accepted chemotherapy,radiotherapy, concurrent radiochemotherapy or who didn't accept therapy, after operation.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
180

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2014

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 17, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 23, 2013

Completed
9 days until next milestone

Study Start

First participant enrolled

January 1, 2014

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

December 23, 2013

Status Verified

November 1, 2013

Enrollment Period

2.8 years

First QC Date

December 17, 2013

Last Update Submit

December 20, 2013

Conditions

Uterine Cervical Neoplasms

Outcome Measures

Primary Outcomes (1)

  • Quality of life for the women with early stage cervical cancer who underwent operation

    up to 12 months after operation

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The women with early stage cervical cancer, who underwent operation in Peking University School of Oncology.

You may qualify if:

  • ≮ 18 years, cervical cancer verified by pathology，
  • IIA stage, accepted the operation ( Piver III and pelvic lymph node dissection) as initial therapy， obtained the patient's agreement

You may not qualify if:

  • the patient had accepted chemotherapy or radiotherapy before operation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Gao Yunong

    Peking University

    STUDY DIRECTOR

Central Study Contacts

Gao Weijiao

CONTACT

86-10-88196102gaoweijiao@126.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
the head of department of gynecological oncology

Study Record Dates

First Submitted

December 17, 2013

First Posted

December 23, 2013

Study Start

January 1, 2014

Primary Completion

October 1, 2016

Study Completion

December 1, 2016

Last Updated

December 23, 2013

Record last verified: 2013-11